Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation

INTRODUCTION: Two antitumor necrosis factor therapies (infliximab [IFX] and adalimumab [ADA]) have been approved for the treatment of pediatric Crohn's disease (CD) but have not been compared in head-to-head trials. The aim of this study was to compare the efficacy and safety of ADA and IFX by...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronsky, Jiri, Copova, Ivana, Kazeka, Denis, Lerchova, Tereza, Mitrova, Katarina, Pospisilova, Kristyna, Sulovcova, Miroslava, Zarubova, Kristyna, Hradsky, Ondrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132518/
https://www.ncbi.nlm.nih.gov/pubmed/35363628
http://dx.doi.org/10.14309/ctg.0000000000000490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132518/
https://www.ncbi.nlm.nih.gov/pubmed/35363628
http://dx.doi.org/10.14309/ctg.0000000000000490

Ejemplares similares